{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:57:15Z","timestamp":1787669835699,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11523-024-01054-z","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T14:02:38Z","timestamp":1714399358000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed\/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study"],"prefix":"10.1007","volume":"19","author":[{"given":"Michael","family":"Maris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Batlevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kagiampakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon C.","family":"Rebelatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndon C.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bothos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Townsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-353X","authenticated-orcid":false,"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"1054_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fcell.2018.00096","volume":"6","author":"M Scalise","year":"2018","unstructured":"Scalise M, Pochini L, Console L, Losso MA, Indiveri C. The Human SLC1A5 (ASCT2) amino acid transporter: from function to structure and role in cell biology. Front Cell Dev Biol. 2018;6:96. https:\/\/doi.org\/10.3389\/fcell.2018.00096.","journal-title":"Front Cell Dev Biol"},{"key":"1054_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejphar.2018.07.007","volume":"837","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhao T, Li Z, Wang L, Yuan S, Sun L. The role of ASCT2 in cancer: a review. Eur J Pharmacol. 2018;837:81\u20137. https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.007.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1054_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","volume":"19","author":"M Hassanein","year":"2013","unstructured":"Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res. 2013;19(3):560\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2334.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1054_CR4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s12253-015-9954-3","volume":"21","author":"O Nikkuni","year":"2015","unstructured":"Nikkuni O, Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, et al. Expression of amino acid transporters (LAT1 and ASCT2) in patients with stage III\/IV laryngeal squamous cell carcinoma. Pathol Oncol Res. 2015;21(4):1175\u201381. https:\/\/doi.org\/10.1007\/s12253-015-9954-3.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"1054_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/his.12464","volume":"66","author":"K Kaira","year":"2015","unstructured":"Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, et al. Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. Histopathology. 2015;66(2):234\u201343. https:\/\/doi.org\/10.1111\/his.12464.","journal-title":"Histopathology"},{"issue":"3","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/path.4518","volume":"236","author":"Q Wang","year":"2015","unstructured":"Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236(3):278\u201389. https:\/\/doi.org\/10.1002\/path.4518.","journal-title":"J Pathol"},{"issue":"24","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/onc.2015.381","volume":"35","author":"M van Geldermalsen","year":"2016","unstructured":"van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, et al. ASCT2\/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35(24):3201\u20138. https:\/\/doi.org\/10.1038\/onc.2015.381.","journal-title":"Oncogene"},{"issue":"8","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1038\/bjc.2014.88","volume":"110","author":"K Shimizu","year":"2014","unstructured":"Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer. 2014;110(8):2030\u20139. https:\/\/doi.org\/10.1038\/bjc.2014.88.","journal-title":"Br J Cancer"},{"issue":"13_Supplement","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"LB-295","DOI":"10.1158\/1538-7445.AM2018-LB-295","volume":"78","author":"NR Monks","year":"2018","unstructured":"Monks NR, Schifferli KP, Tammali R, Borrok MJ, Coats SR, Herbst R, et al. MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies. Cancer Res. 2018;78(13_Supplement):LB-295. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-LB-295.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1182\/blood-2018-99-119836","volume":"132","author":"N Pore","year":"2018","unstructured":"Pore N, Schifferli KP, Monks NR, Tammali R, Borrok M, Hurt E, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers. Blood. 2018;132(Supplement 1):4071. https:\/\/doi.org\/10.1182\/blood-2018-99-119836.","journal-title":"Blood"},{"issue":"16","key":"1054_CR11","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138. https:\/\/doi.org\/10.1182\/blood-2017-03-769620.","journal-title":"Blood"},{"key":"1054_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110429","author":"M Luppi","year":"2018","unstructured":"Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A. Novel agents for acute myeloid leukemia. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers10110429.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1054_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1085\/jgp.201812276","volume":"151","author":"E Ndaru","year":"2019","unstructured":"Ndaru E, Garibsingh RA, Shi Y, Wallace E, Zakrepine P, Wang J, et al. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds. J Gen Physiol. 2019;151(3):357\u201368. https:\/\/doi.org\/10.1085\/jgp.201812276.","journal-title":"J Gen Physiol"},{"issue":"7","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/0192623318803059","volume":"46","author":"L Mecklenburg","year":"2018","unstructured":"Mecklenburg L. A brief introduction to antibody-drug conjugates for toxicologic pathologists. Toxicol Pathol. 2018;46(7):746\u201352. https:\/\/doi.org\/10.1177\/0192623318803059.","journal-title":"Toxicol Pathol"},{"issue":"1","key":"1054_CR15","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","volume":"8","author":"JA Hartley","year":"2018","unstructured":"Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479. https:\/\/doi.org\/10.1038\/s41598-018-28533-4.","journal-title":"Sci Rep"},{"issue":"1","key":"1054_CR16","first-page":"3","volume":"11","author":"MR Nejadmoghaddam","year":"2019","unstructured":"Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani AH. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11(1):3\u201323.","journal-title":"Avicenna J Med Biotechnol."},{"issue":"6","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7(6):653\u201363. https:\/\/doi.org\/10.1177\/1740774510382799.","journal-title":"Clin Trials"},{"issue":"4","key":"1054_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"8","key":"1054_CR19","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"27","key":"1054_CR20","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1054_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMc1608739","volume":"375","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Dohner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375(9):900\u20131. https:\/\/doi.org\/10.1056\/NEJMc1608739.","journal-title":"N Engl J Med"},{"issue":"7","key":"1054_CR22","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2018","unstructured":"Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin NP, Schneider S, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598\u2013608. https:\/\/doi.org\/10.1038\/s41375-018-0034-z.","journal-title":"Leukemia"},{"issue":"5","key":"1054_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/2040620715596715","volume":"6","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253\u201361. https:\/\/doi.org\/10.1177\/2040620715596715.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"1054_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","volume":"3","author":"J Wynne","year":"2019","unstructured":"Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019;3(1):96\u2013104. https:\/\/doi.org\/10.1182\/bloodadvances.2018026211.","journal-title":"Blood Adv"},{"key":"1054_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","volume":"7","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24. https:\/\/doi.org\/10.1186\/s40364-019-0175-x.","journal-title":"Biomark Res"},{"issue":"2","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","volume":"37","author":"T Phillips","year":"2019","unstructured":"Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2019;37(2):297\u2013306. https:\/\/doi.org\/10.1007\/s10637-018-0655-0.","journal-title":"Invest New Drugs"},{"issue":"5","key":"1054_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","volume":"65","author":"YY Janjigian","year":"2010","unstructured":"Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol. 2010;65(5):833\u20138. https:\/\/doi.org\/10.1007\/s00280-009-1088-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","volume":"25","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1133.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/hep.30222","volume":"69","author":"GB McDonald","year":"2019","unstructured":"McDonald GB, Freston JW, Boyer JL, DeLeve LD. Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin). Hepatology. 2019;69(2):831\u201344. https:\/\/doi.org\/10.1002\/hep.30222.","journal-title":"Hepatology"},{"issue":"10200","key":"1054_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(19)31774-X.","journal-title":"Lancet"},{"issue":"9","key":"1054_CR31","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","volume":"16","author":"H Zhao","year":"2017","unstructured":"Zhao H, Gulesserian S, Ganesan SK, Ou J, Morrison K, Zeng Z, et al. Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia. Mol Cancer Ther. 2017;16(9):1877\u201386. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0710.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1054_CR32","first-page":"829","volume":"24","author":"R Ramesh","year":"1996","unstructured":"Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the \u201cbystander effect\u201d: a cytokine cascade. Exp Hematol. 1996;24(7):829\u201338.","journal-title":"Exp Hematol"},{"issue":"21","key":"1054_CR33","first-page":"5274","volume":"53","author":"SM Freeman","year":"1993","unstructured":"Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The \u201cbystander effect\u201d: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53(21):5274\u201383.","journal-title":"Cancer Res"},{"key":"1054_CR34","unstructured":"Cancer Cell Line Encyclopedia. 2021. https:\/\/portals.broadinstitute.org\/ccle."},{"issue":"6","key":"1054_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12032-017-0970-x","volume":"34","author":"FA Lagunas-Rangel","year":"2017","unstructured":"Lagunas-Rangel FA, Chavez-Valencia V. FLT3-ITD and its current role in acute myeloid leukaemia. Med Oncol. 2017;34(6):114. https:\/\/doi.org\/10.1007\/s12032-017-0970-x.","journal-title":"Med Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01054-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01054-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01054-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:22:03Z","timestamp":1716384123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01054-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01054-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"10 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael Maris: None. Gilles Salles: Financial compensation for participating in advisory boards or consulting from: Abbvie, BMS\/Celgene, Debiopharm, Epizyme, Genentech\/Roche, Incyte, Janssen, Kite\/Gilead, Epizyme, Miltenyi, Morphosys, Novartis, VelosBio; and for participation in educational events from: Kite Pharma\/Gilead Sciences. Won Seog Kim: Nothing to disclose. Tae Min Kim: Advisory or consultant roles for AstraZeneca, Novartis, Takeda, Sanofi, Roche\/Genentech, and Boryung. Research funding from AstraZeneca and Korea Health Industry Development Institute outside this work. Roger Lyons: Consultancy and Advisory boards for ABBVie, Argenx, AstraZeneca, BriGene, Celgene, INCYTE, IQVIA, Karyopharm, Taiho, and Takeda. Martha Arellano: Advisory board member for Kite Pharma, Inc, Gilead Sciences, Inc, and Syndax Pharmaceuticals, Inc. Reem Karmali: Consulting Fees:\u00a0Celgene Corporation, Gilead Sciences, Inc, Juno Therapeutics, Kite Pharma, OncLive, Verastem, Janssen, Karyopharm, Morphosys; Grants\/Research; Support:\u00a0Celgene Corporation, Juno Therapeutics, BMS, Takeda, BeiGene, AstraZeneca; Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc, Juno Therapeutics, Kite Pharma, AstraZeneca, BeiGene, Morphosys. Gary Schiller: Stock and Other Ownership Interests: Bristol Myers Squibb, Amgen, Johnson & Johnson; Consulting or Advisory Role: Ono Pharmaceutical, Agios, Celgene, Incyte, Jazz Pharmaceuticals, Novartis, AbbVie, Astellas Pharma; Speakers' Bureau: Astellas Pharma, Kite, a Gilead Company, Jazz Pharmaceuticals, Stemline Therapeutics, Bristol Myers Squibb, Sanofi, Karyopharm Therapeutics, Incyte, AbbVie; Research Funding: AbbVie, Actinium Pharmaceuticals, Actuate Therapeutics, Arog, Astellas Pharma, Bristol Myers Squibb\/Celgene, Celator, Constellation Pharmaceuticals, Daiichi Sankyo, Deciphera, Delta-Fly Pharma, FORMA Therapeutics, Fujifilm, Gamida Cell, Genentech\/Roche, Geron, Incyte, Karyopharm Therapeutics, Kite, a Gilead Company, Mateon Therapeutics, Onconova Therapeutics, Pfizer, Precog, REGiMMUNE, Samus Therapeutics, Sangamo Bioscience, SELLAS Life Sciences, Stemline Therapeutics, Takeda, Tolero Pharmaceuticals, Trovagene, Agios, Amgen, Jazz Pharmaceuticals, ElevateBio, Ono Pharmaceutical, Novartis, Sanofi, AVM Biotechnology, Syros Pharmaceuticals. Elizabeth Cull: Speaker for Bristol Myers Squibb. Camille N. Abboud: Clinical research support from Novartis, Gilead, and Ryvu. Connie Batlevi: Research Funding: Janssen, Novartis, Epizyme, Xynomics, Bayer, Autolus, Roche; Consulting\/Advisory Boards: Life Sci, GLG, Juno\/Celgene, Seattle Genetics, Kite Pharma, Karyopharm, TG Therapeutics, ADC Therapeutics; Honorarium: Dava Oncology, TouchIME, Medscape; Stock ownership: BMS, Pfizer, Viatris, Regeneron, Moderna, Novavax. Ioannis Kagiampakis: Employee of AstraZeneca and may own stock or stock options. Marlon C. Rebelatto: Employee of AstraZeneca and may own stock or stock options. Young Lee: Employee of AstraZeneca and may own stock or stock options. Lyndon C. Kirby: Employee of AstraZeneca and may own stock or stock options. Fujun Wang: Employee of AstraZeneca and may own stock or stock options. Current equity holder in a publicly traded company. John Bothos: Employee of AstraZeneca and may own stock or stock options. Danielle M Townsley: Employee of AstraZeneca and may own stock or stock options. Amir T. Fathi: Consulting\/Advisory Fees: Celgene\/BMS, Foghorn, Kite Pharma, Morphosys, Abbvie, Agios, Genentech, Takeda, Pfizer, Trillium, Kura Oncology, Blueprint, Astellas; Grants\/Research Support: Celgene\/BMS, Abbvie, Agios. Vincent Ribrag: Advisory boards for Gilead, Infinity, MSD, BMS, Nanostring, Incyte, Roche, AstraZeneca, Servier; Research support from Argen-X and Astex.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data underlying the findings described in this article may be obtained in accordance with AstraZeneca\u2019s data-sharing policy, described at: .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study protocol was approved by an institutional review board or independent ethics committee at each study site. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation\/Good Clinical Practice.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Investigators on the trial: MM, GS, WSK, TMK, RML, MA, RK, GS, EC, CAN, CB, ATF, VR. Members of the Steering Committee: MM. Provided clinical and scientific input to the study design and study protocol: MM, YL (design and protocol for TM exploratory biomarker analyses), MR (design and protocol for PD-L1 IHC assessment). Trial statistician: FW. Interpreted the data: YL, IK, MR, MM. TM contributors: IK, MR, YL. All authors had full access to the data and analyses and vouch for the accuracy and integrity, and for the fidelity of the study to the protocol. All authors were involved in review of each draft of the manuscript and the decision to submit.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}